


1/11/06

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,CH2

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:18:17 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 184 TO ITERATE

100.0% PROCESSED 184 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2867 TO 4493

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 12:18:21 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3499 TO ITERATE

100.0% PROCESSED 3499 ITERATIONS

45 ANSWERS

SEARCH TIME: 00.00.01

L3 45 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.99

FILE 'CAPLUS' ENTERED AT 12:18:24 ON 11 JAN 2006

10799681

1/11/06

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 10 Jan 2006 (20060110/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:



<http://www.cas.org/infopolicy.html>

=> s l3

L4 6 L3

=> d abs fbib hitstr 1-6

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



AB Aryloxyphenyl diethylaminopropanone hydrochlorides I•HCl [R = H, Br,

10799681

1/11/06

Cl, F, Me; R1 = R2 = Me, Et; R1R2 = (CH2)4, (CH2)5, (CH2)2O(CH2)2; X = O, S] and (aryloxybenzoyl)piperidinol salts II•HY (R3 = H, F, Br, Cl, Me; Y = Br, Cl) are prepared as potential antitumor agents by Mannich reactions. I and II display cytotoxic and anticancer activities towards mouse and human cell lines, T-lymphocytes, and human colon cancer cell lines; the activities of I and II towards colon cancer cell lines is comparable to those of mephalan and 5-fluorouracil. The anticancer activities of II are generally higher than those of I. The mol. structures of I (R = H; R1 = R2 = Et; X = O) and II (R3 = H) are calculated to determine the structural features

that lead to the differences in anticancer activity between I and II. II did not show toxicity in mice at doses of up to 300 mg/kg; I show toxicity in mice at doses of either 30 mg/kg or 100 mg/kg in mice. I may be used as lead compds. for the development of anticonvulsant agents; I (R = Cl; R1 = R2 = Et; X = O) showed oral anticonvulsant activity in mice at doses of 12.5 mg/kg and 30 mg/kg while lacking toxicity in mice at those doses.

AN 2004:153853 CAPLUS

DN 140:423555

TI Cytotoxic and anticonvulsant aryloxyaryl Mannich bases and related compounds

AU Vashishtha, Sarvesh C.; Zello, Gordon A.; Nienaber, Kurt H.; Balzarini, Jan; De Clercq, Erik; Stables, James P.; Dimmock, Jonathan R.

CS College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, S7N 5C9, Can.

SO European Journal of Medicinal Chemistry (2004), 39(1), 27-35

CODEN: EJMCA5; ISSN: 0223-5234

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 140:423555

IT 691907-12-7P 691907-13-8P 691907-14-9P
691907-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(stereoselective preparation and murine toxicity of aryloxybenzoylpiperidinol hydrochlorides prepared as antitumor and anticonvulsant agents and as cytotoxic agents against cancer and T cells)

RN 691907-12-7 CAPLUS

CN Methanone, [(3R,4R)-1-ethyl-4-[4-(4-fluorophenoxy)phenyl]-4-hydroxy-3-piperidinyl][4-(4-fluorophenoxy)phenyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


1/11/06



RN 691907-13-8 CAPLUS

CN Methanone, [4-(4-chlorophenoxy)phenyl] [(3R,4R)-4-[4-(4-chlorophenoxy)phenyl]-1-ethyl-4-hydroxy-3-piperidinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 691907-14-9 CAPLUS

CN Methanone, [4-(4-bromophenoxy)phenyl] [(3R,4R)-4-[4-(4-bromophenoxy)phenyl]-1-ethyl-4-hydroxy-3-piperidinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10799681


1/11/06



RN 691907-15-0 CAPLUS

CN Methanone, [(3R,4R)-1-ethyl-4-hydroxy-4-[4-(4-methylphenoxy)phenyl]-3-piperidinyll-4-(4-methylphenoxy)phenyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 691907-11-6P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(stereoselective preparation, murine toxicity, and mol. structure-antitumor activity correlation of an aryloxybenzoylpiperidinol hydrochloride prepared as an antitumor, anticonvulsant agent and as a cytotoxic agent against cancer and T cells)


RN 691907-11-6 CAPLUS

CN Methanone, [(3R,4R)-1-ethyl-4-hydroxy-4-(4-phenoxyphenyl)-3-piperidinyll-4-phenoxyphenyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10799681


1/11/06



● HCl

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



AB Compds. W-(CR₆R₇)yCH(G)(CR₄R₅)xCO-X(R₁)CHR₂(CHR₃)r(CH₂)sCO-E [X = N or CH; R₁, R₃ = H or alkyl; R₂ = H, aryl, cycloalkyl, heteroaryl, heterocyclyl, (un)substituted alkyl or alkenyl; R₁ together with R₂ or R₃ or R₂ together with R₃ form mono- or bicyclic aryl, cycloalkyl, heteroaryl, or heterocyclyl; E = (un)substituted pyrrolidino, piperidino, hexahydro-1-azepinyl, 1-piperazinyl, cyclopentyl, cyclohexyl, cycloheptyl, amino, (cyclo)alkylamino; R₄-R₆ = H, (un)substituted alkyl, amino, alkylamino, hydroxy, alkoxy, aryl, cycloalkyl, heteroaryl, or heterocyclyl; or CR₄R₅ or C₆R₇ is a spirocycloalkyl ring; r, s = 0 or 1; x = 0-4; y = 0-2; G = alkenyl, arylalkenyl, hydroxy, heteroaryl, cyano, functionalized alkyl or alkenyl, etc.; W = amino, alkylamino, hydroxy, alkoxy, carbamoyl, amidino, cycloalkyl, heteroaryl, heterocyclyl, etc.] were prepared as modulators of melanocortin receptors, particularly MC-1R and MC-4R. Thus, peptide I was prepared by a solution-phase peptide coupling/deprotection scheme.

AN 2002:695975 CAPLUS

DN 137:232913

TI Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors

IN Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl

10799681

1/11/06

PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070511	A1	20020912	WO 2002-US6479	20020302
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
	CA 2437594	AA	20020912	CA 2002-2437594	20020302
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
				WO 2002-US6479	W 20020302
EP 1363898		A1	20031126	EP 2002-723310	20020302
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
				WO 2002-US6479	W 20020302
JP 2005511475		T2	20050428	JP 2002-569831	20020302
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
				WO 2002-US6479	W 20020302
US 2003092732		A1	20030515	US 2002-90582	20020304
US 6979691		B2	20051227		
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
US 2003096827		A1	20030522	US 2002-90288	20020304
US 6713487		B2	20040330		
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
US 2004229882		A1	20041118	US 2003-696761	20031029
				US 2001-273206P	P 20010302
				US 2001-273291P	P 20010302
				US 2002-90288	A3 20020304

PATENT FAMILY INFORMATION:

FAN 2002:695727

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069905	A2	20020912	WO 2002-US6805	20020304
	WO 2002069905	A3	20031009		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

10799681

1/11/06

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2001-289719P	P	20010509
CA 2439691	AA	20020912	CA 2002-2439691		20020304
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2001-289719P	P	20010509
US 2003069169	A1	20030410	WO 2002-US6805	W	20020304
			US 2002-90258		20020304
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2001-289719P	P	20010509
EP 1370211	A2	20031217	EP 2002-713772		20020304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2001-289719P	P	20010509
			WO 2002-US6805	W	20020304
JP 2005506286	T2	20050303	JP 2002-569083		20020304
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2001-289719P	P	20010509
			WO 2002-US6805	W	20020304
US 2004229882	A1	20041118	US 2003-696761		20031029
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2002-90288	A3	20020304
FAN 2002:777885					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	----	-----	-----	-----	
PI WO 2002079146	A2	20021010	WO 2002-US6581		20020302
WO 2002079146	A3	20030206			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
CA 2438272	AA	20021010	CA 2002-2438272		20020302
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			WO 2002-US6581	W	20020302
EP 1363631	A2	20031126	EP 2002-741644		20020302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			WO 2002-US6581	W	20020302
JP 2004532838	T2	20041028	JP 2002-577773		20020302
			US 2001-273206P	P	20010302

10799681

1/11/06

US 2003092732	A1	20030515	US 2001-273291P	P	20010302
US 6979691	B2	20051227	WO 2002-US6581	W	20020302
			US 2002-90582		20020304
US 2003096827	A1	20030522	US 2001-273206P	P	20010302
US 6713487	B2	20040330	US 2001-273291P	P	20010302
			US 2002-90288		20020304
US 2004229882	A1	20041118	US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2003-696761		20031029
			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2002-90288	A3	20020304

OS MARPAT 137:232913

IT 457904-14-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457904-14-2 CAPLUS


CN 1H-Imidazole-4-propanamide, α -(acetylamino)-N-[(1S)-2-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I


10799681

1/11/06

AB A series of novel 4-arylpiperidines and 4-aryl-4-piperidinols was synthesized and evaluated for blocking effects on both neuronal Na⁺ and T-type Ca²⁺ channels and binding affinity for dopamine D2 receptors. Most of the compds. blocked both ion channels with potency greater than or equal to flunarizine which was used as a reference standard. In addition, these compds. had significantly reduced affinity for dopamine D2 receptors which is common in this class of structure. Some of the compds. exhibited potent anticonvulsant effects on audiogenic seizures in DBA/2 mice, indicating their excellent brain permeability. Neuroprotective activity was also assessed in a transient middle cerebral artery occlusion (MCAO) model. Three compds. significantly reduced neuronal damage without affecting ischemic hyperthermia, while flunarizine produced only minor redns. In particular, I had 1.7-fold the potency in this MCAO model but only 1/20 the affinity for dopamine D2 receptors as flunarizine. Cinnamyl, phenacyl and phenoxypropanol groups appeared to be structurally and biol. equivalent. Moreover, di-Ph ether and biphenyl groups occupy a similar space, suggesting that both groups act as a bioisostere for the blockade of ion channels; however, this is not the case for dopamine D2 receptors since only biphenyl compds. had high affinity similar to flunarizine. Compound I (SUN N5030) has a good pharmacol. profile and may be useful in the alleviation and treatment of ischemic diseases.

AN 2001:900245 CAPLUS
DN 136:272649
TI Synthesis and biological evaluation of new 4-arylpiperidines and 4-aryl-4-piperidinols: dual Na⁺ and Ca²⁺ channel blockers with reduced affinity for dopamine D2 receptors
AU Annoura, Hirokazu; Nakanishi, Kyoko; Uesugi, Mayumi; Fukunaga, Atsuko; Imajo, Seiichi; Miyajima, Atsuko; Tamura-Horikawa, Yoshiko; Tamura, Shigeki
CS Suntory Biomedical Research Limited, Mishima-gun, Shimamoto-cho, Wakayamadaai, Osaka, 618-8503, Japan
SO Bioorganic & Medicinal Chemistry (2001), Volume Date 2002, 10(2), 371-383
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:272649
IT 202716-63-0P 202716-65-2P 202716-67-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of arylpiperidines and arylpiperidinols as dual Na⁺ and Ca²⁺ channel blockers with reduced affinity for dopamine D2 receptors)
RN 202716-63-0 CAPLUS
CN 4-Piperidinol, 4-(4-phenoxyphenyl)-1-[(2E)-3-phenyl-2-propenyl]- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




10799681

1/11/06


RN 202716-65-2 CAPLUS

CN Ethanone, 2-[4-hydroxy-4-(4-phenoxyphenyl)-1-piperidinyl]-1-phenyl- (9CI)
(CA INDEX NAME)



RN 202716-67-4 CAPLUS

CN 1-Piperidineethanol, 4-hydroxy- α -(phenoxyethyl)-4-(4-phenoxyphenyl)-
(9CI) (CA INDEX NAME)




IT 202604-70-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of arylpiperidines and arylpiperidinols as dual Na⁺ and Ca²⁺
channel blockers with reduced affinity for dopamine D2 receptors)

RN 202604-70-4 CAPLUS

CN 4-Piperidinol, 4-(4-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX
NAME)



IT 202716-66-3P 202716-68-5P 406720-85-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of arylpiperidines and arylpiperidinols as dual Na⁺ and Ca²⁺
channel blockers with reduced affinity for dopamine D2 receptors)

RN 202716-66-3 CAPLUS


CN Ethanone, 2-[4-hydroxy-4-(4-phenoxyphenyl)-1-piperidinyl]-1-phenyl-,
(2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-65-2

CMF C25 H25 N O3

1/11/06




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 202716-68-5 CAPLUS

CN 1-Piperidineethanol, 4-hydroxy- α -(phenoxyethyl)-4-(4-phenoxyphenyl)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-67-4

CMF C26 H29 N O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 406720-85-2 CAPLUS

CN 4-Piperidinol, 4-(4-phenoxyphenyl)-1-[(2E)-3-phenyl-2-propenyl]-, hydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10799681



1/11/06



● HCl

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



AB The title compds. (I; R = H, optionally substituted Ph, phenoxy or benzoyl; A = a bond, cycloalkylene or alkenylene optionally substituted by lower alkyl; B = alkylene optionally substituted by OH or alkoxy, etc.; E = a bond, O, CH₂; X = OH or H, provided that X is not H when E is O or CH₂; Y, Z = H, halo, alkoxy or optionally halogenated alkyl) are prepared I are useful for improving or treating symptoms on the basis of ischemic diseases, convulsion, epilepsy and symptoms originating in hemicrania and calcium ion superloading inhibitors. Thus, N-benzyl-4-piperidone was reacted with (3-fluoro-4-phenyl)phenylmagnesium bromide (preparation given) to give 62% the title compound (II). I showed inhibitory activity for veratridine induced sodium channel and T-type calcium ion channel inhibitory activity when tested with wistar rat.

AN 1998:87609 CAPLUS

DN 128:154012

TI Preparation of arylpiperidinol and arylpiperidine derivatives

IN Annoura, Hirokazu; Nakanishi, Kyoko; Tamura, Shigeki

10799681


1/11/06

PA Suntory Ltd., Japan; Annoura, Hirokazu; Nakanishi, Kyoko; Tamura, Shigeki
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803172	A1	19980129	WO 1997-JP2531	19970722
	W: AU, CA, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				JP 1996-192123	A 19960722
				WO 1996-JP2613	A2 19960912
	CA 2231879	AA	19980129	CA 1997-2231879	19970722
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
	AU 9734640	A1	19980210	AU 1997-34640	19970722
	AU 710594	B2	19990923		
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
	EP 867183	A1	19980930	EP 1997-930865	19970722
	EP 867183	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
	AT 278402	E	20041015	AT 1997-930865	19970722
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
	ES 2225979	T3	20050316	ES 1997-930865	19970722
				JP 1996-192123	A 19960722
	US 6455549	B1	20020924	US 1998-43563	19980320
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
	US 2003130312	A1	20030710	US 2002-196362	20020717
	US 6706734	B2	20040316		
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
				US 1998-43563	A3 19980320
	US 2004186138	A1	20040923	US 2004-799681	20040315
				JP 1996-192123	A 19960722
				WO 1997-JP2531	W 19970722
				US 1998-43563	A3 19980320
				US 2002-196362	A3 20020717
OS	MARPAT 128:154012				
IT	202604-70-4P 202716-27-6P 202716-64-1P				
	202716-66-3P 202716-68-5P 202716-86-7P				
	202716-88-9P 202716-94-7P 202716-96-9P				
	202717-02-0P 202717-06-4P 202717-10-0P				
	202717-12-2P 202717-14-4P 202717-16-6P				
	202717-18-8P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(Preparation of arylpiperidinol and arylpiperidine derivs.)				
RN	202604-70-4 CAPLUS				
CN	4-Piperidinol, 4-(4-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)				


10799681

1/11/06



RN 202716-27-6 CAPLUS

CN 4-Piperidinol, 4-[4-(4-fluorophenoxy)phenyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 202716-64-1 CAPLUS


CN 4-Piperidinol, 4-(4-phenoxyphenyl)-1-[(2E)-3-phenyl-2-propenyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-63-0

CMF C26 H27 N O2

Double bond geometry as shown.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 202716-66-3 CAPLUS

CN Ethanone, 2-[4-hydroxy-4-(4-phenoxyphenyl)-1-piperidinyl]-1-phenyl-,

10799681


1/11/06

(2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-65-2

CMF C25 H25 N O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 202716-68-5 CAPLUS

CN 1-Piperidineethanol, 4-hydroxy- α -(phenoxymethyl)-4-(4-phenoxyphenyl)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-67-4

CMF C26 H29 N O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 202716-86-7 CAPLUS

10799681

1/11/06


CN 1-Piperidineethanol, 4-hydroxy- α -(phoxymethyl)-4-(4-phenoxyphenyl)-
, (S)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-85-6

CMF C26 H29 N O4

Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 202716-88-9 CAPLUS


CN 1-Piperidineethanol, 4-hydroxy- α -(phoxymethyl)-4-(4-phenoxyphenyl)-
, (R)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-87-8

CMF C26 H29 N O4

Absolute stereochemistry. Rotation (+).



CM 2


CRN 110-17-8

CMF C4 H4 O4

10799681

1/11/06

Double bond geometry as shown.




RN 202716-94-7 CAPLUS

CN 4-Piperidinol, 4-(4-phenoxyphenyl)-1-[(1-phenylcyclopropyl)methyl]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-93-6

CMF C27 H29 N O2




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 202716-96-9 CAPLUS


CN 4-Piperidinol, 4-(4-phenoxyphenyl)-1-[[[(1R,2R)-2-phenylcyclopropyl]methyl]-, rel-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202716-95-8

CMF C27 H29 N O2

Relative stereochemistry.




CM 2

10799681

1/11/06

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 202717-02-0 CAPLUS
CN 1-Piperidineacetamide, 4-hydroxy-4-(4-phenoxyphenyl)-N-[(1R,2R)-2-phenylcyclopropyl]-, rel-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202717-01-9
CMF C28 H30 N2 O3


Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 202717-06-4 CAPLUS
CN 1-Piperidineacetamide, N-(2,6-dimethylphenyl)-4-hydroxy-4-(4-phenoxyphenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202717-05-3
CMF C27 H30 N2 O3

10799681

1/11/06




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 202717-10-0 CAPLUS

CN 1-Piperidineacetamide, 4-hydroxy-4-(4-phenoxyphenyl)-N-(1-phenylcyclopropyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202717-09-7

CMF C28 H30 N2 O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 202717-12-2 CAPLUS


CN 1-Piperidineacetamide, 4-[4-(4-fluorophenoxy)phenyl]-4-hydroxy-N-(1-phenylcyclopropyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

10799681

1/11/06


CRN 202717-11-1
CMF C28 H29 F N2 O3



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 202717-14-4 CAPLUS
CN 4-Piperidinol, 4-[4-(4-fluorophenoxy)phenyl]-1-[(2E)-3-phenyl-2-propenyl]-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202717-13-3
CMF C26 H26 F N O2


Double bond geometry as shown.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



10799681

1/11/06


RN 202717-16-6 CAPLUS

CN Ethanone, 2-[4-[4-(4-fluorophenoxy)phenyl]-4-hydroxy-1-piperidinyl]-1-phenyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202717-15-5

CMF C25 H24 F N O3




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 202717-18-8 CAPLUS


CN 1-Piperidineethanol, 4-[4-(4-fluorophenoxy)phenyl]-4-hydroxy- α -(phoxymethyl)-, (S)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 202717-17-7

CMF C26 H28 F N O4

Absolute stereochemistry. Rotation (-).




CM 2

10799681

1/11/06


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI



I

AB Title compds. (I; R₁ = alkyl; R₂, R₃ = cyano, alkyl; R₄ = CO₂R₁, 3-methyl-1,2,4-oxadiazol-5-yl; R₅ = H, halo, OH, alkyl, alkoxy, alkenyloxy; B = NH, NR₁, O, bond; n = 2-5; Z = 4-substituted-piperidin-1-yl, 4-substituted-1,2,3,6-tetrahydropiperidin-1-yl, etc.), were prepared for promoting weight loss and treating eating disorders (no data). Thus, di-Me 1,4-dihydro-4-[3-[[3-chloro-1-oxo-1-propyl]amino]phenyl]-1,6-dimethyl-3,5-pyridinedicarboxylate, 4-phenylpiperidine, and K₂CO₃ were refluxed 24 h in MeCN to give 100% di-Me 1,4-dihydro-4-[3-[[3-(4-phenylpiperidin-1-yl)-1-oxo-1-propyl]amino]phenyl]-2,6-dimethyl-3,5-piperidinedicarboxylate.

AN 1997:636061 CAPLUS

DN 127:293135

TI Preparation of piperidinylalkylphenyldihydropyridinecarboxylate derivatives as neuropeptide Y antagonists.

IN Poindexter, Graham S.; Bruce, Marc; Johnson, Graham; Leboulluec, Karen; Sloan, Charles P.

PA Bristol-Myers Squibb Company, USA

SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 482,353, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5668151	A	19970916	US 1996-639968	19960508
				US 1995-482353	B2 19950607
	CA 2177110	AA	19961208	CA 1996-2177110	19960522
				US 1995-482353	A 19950607
	AT 211733	E	20020115	AT 1996-109043	19960605

10799681

1/11/06

PT 747357	T	20020628	US 1995-482353	A	19950607
			PT 1996-109043		19960605
ES 2169774	T3	20020716	US 1995-482353	A	19950607
			ES 1996-109043		19960605
AU 9654758	A1	19961219	US 1995-482353	A	19950607
AU 720923	B2	20000615	AU 1996-54758		19960606
			US 1995-482353	A	19950607
JP 09003045	A2	19970107	JP 1996-145272		19960607
			US 1995-482353	A	19950607

PATENT FAMILY INFORMATION:

FAN 1997:111046

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 747357	A2	19961211	EP 1996-109043	19960605
	EP 747357	A3	19981216		
	EP 747357	B1	20020109		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				

CA 2177110	AA	19961208	US 1995-482353	A	19950607
			CA 1996-2177110		19960522
			US 1995-482353	A	19950607
AT 211733	E	20020115	AT 1996-109043		19960605
			US 1995-482353	A	19950607
PT 747357	T	20020628	PT 1996-109043		19960605
			US 1995-482353	A	19950607
ES 2169774	T3	20020716	ES 1996-109043		19960605
			US 1995-482353	A	19950607
AU 9654758	A1	19961219	AU 1996-54758		19960606
AU 720923	B2	20000615			
			US 1995-482353	A	19950607
JP 09003045	A2	19970107	JP 1996-145272		19960607
			US 1995-482353	A	19950607

OS MARPAT 127:293135

IT 186185-23-9P 186185-51-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidinylalkylphenyldihydropyridinecarboxylate derivs. as neuropeptide Y antagonists)

RN 186185-23-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


1/11/06



● HCl

RN 186185-51-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)




IT 186185-96-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidinylalkylphenyldihydropyridinecarboxylate derivs. as neuropeptide Y antagonists)

RN 186185-96-6 CAPLUS


CN 4-Piperidinol, 4-(2-phenoxyphenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
GI

10799681

1/11/06



AB Title compds. [I; R = C₆H₃R₅R₆-4,3; R₁ alkyl; R₂,R₃ = cyano or alkyl; R₄ = cyano, CO₂R₁, 3-methyl-1,2,4-oxadiazol-5-yl; R₅ = H, halo, alkyl, alkoxy; R₆ = NHCOZ(CH₂)_nR₇; R₇ = 4-arylpiperidino, 4-aryl-1,2,3,6-tetrahydropyridinyl, etc.; Z = bind, O, (alkyl)imino; n = 2-5] were prepared. Thus, MeCOCH₂CO₂Bu was cyclocondensed with MeC(NH₂):CHCO₂Me and 3-(O₂N)C₆H₄CHO to give I (R₁ = R₂ = R₃ = Me) [II; R = C₆H₄(NO₂)-3, R₄ = CO₂Bu]. II [R₄ = CO₂Me, R = C₆H₄(NO₂)-3] was converted in 2 steps to title compound III (R₇ = Cl) which was aminated by 4-phenylpiperidine to give III (R₇ = 4-phenylpiperidino). Data for biol. activity of I were given.

AN 1997:111046 CAPLUS

DN 126:117870

TI Preparation of 4-(3-carboxamidophenyl)-1,4-dihydropyridine-3,5-dicarboxylates as neuropeptide Y antagonists

IN Poindexter, Graham S.; Bruce, Marc; Johnson, Graham; Leboulluec, Karen; Sloan, Charles P.

PA Bristol-Myers Squibb Company, USA

SO Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 747357	A2	19961211	EP 1996-109043	19960605
	EP 747357	A3	19981216		
	EP 747357	B1	20020109		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2177110	AA	19961208	US 1995-482353	A 19950607
				CA 1996-2177110	19960522
				US 1995-482353	A 19950607
	AT 211733	E	20020115	AT 1996-109043	19960605
				US 1995-482353	A 19950607
	PT 747357	T	20020628	PT 1996-109043	19960605
				US 1995-482353	A 19950607
	ES 2169774	T3	20020716	ES 1996-109043	19960605
				US 1995-482353	A 19950607
	AU 9654758	A1	19961219	AU 1996-54758	19960606
	AU 720923	B2	20000615		
				US 1995-482353	A 19950607
	JP 09003045	A2	19970107	JP 1996-145272	19960607
				US 1995-482353	A 19950607

PATENT FAMILY INFORMATION:

FAN 1997:636061

10799681

1/11/06

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5668151	A	19970916	US 1996-639968	19960508
				US 1995-482353	B2 19950607
	CA 2177110	AA	19961208	CA 1996-2177110	19960522
				US 1995-482353	A 19950607
	AT 211733	E	20020115	AT 1996-109043	19960605
				US 1995-482353	A 19950607
	PT 747357	T	20020628	PT 1996-109043	19960605
				US 1995-482353	A 19950607
	ES 2169774	T3	20020716	ES 1996-109043	19960605
				US 1995-482353	A 19950607
	AU 9654758	A1	19961219	AU 1996-54758	19960606
	AU 720923	B2	20000615		
	JP 09003045	A2	19970107	US 1995-482353	A 19950607
				JP 1996-145272	19960607
				US 1995-482353	A 19950607


OS MARPAT 126:117870

IT 186185-23-9P 186185-51-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(3-carboxamidophenyl)-1,4-dihydropyridine-3,5-dicarboxylates as neuropeptide Y antagonists)

RN 186185-23-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 186185-51-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-4-[3-[[[3-[4-hydroxy-4-(2-phenoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-, dimethyl ester (9CI) (CA INDEX NAME)

10799681

1/11/06




IT 186185-96-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-(3-carboxamidophenyl)-1,4-dihydropyridine-3,5-dicarboxylates as neuropeptide Y antagonists)

RN 186185-96-6 CAPLUS

CN 4-Piperidinol, 4-(2-phenoxypiperidin-1-yl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



=>

10799681